Smith & Nephew plc (NYSE:SNN) declared a Semi-Annual dividend on Wednesday, July 29th, Zacks reports. Investors of record on Friday, October 2nd will be given a dividend of 0.278 per share by the medical equipment provider on Wednesday, October 28th. The ex-dividend date is Thursday, October 1st.
Smith & Nephew has raised its dividend payment by an average of 16.3% per year over the last three years and has raised its dividend every year for the last 1 years. Smith & Nephew has a dividend payout ratio of 58.4% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Smith & Nephew to earn $2.02 per share next year, which means the company should continue to be able to cover its $0.90 annual dividend with an expected future payout ratio of 44.6%.
SNN traded down $0.87 during trading on Friday, reaching $40.05. 9,425 shares of the company’s stock were exchanged, compared to its average volume of 439,660. Smith & Nephew has a fifty-two week low of $26.07 and a fifty-two week high of $52.26. The firm has a market capitalization of $17.78 billion, a PE ratio of 20.06, a P/E/G ratio of 6.86 and a beta of 0.56. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.03 and a current ratio of 2.06. The company’s fifty day moving average price is $40.15 and its 200-day moving average price is $41.62.
Several equities analysts have recently issued reports on SNN shares. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Smith & Nephew in a report on Thursday. Morgan Stanley reissued an “overweight” rating on shares of Smith & Nephew in a report on Thursday. BNP Paribas lowered shares of Smith & Nephew from a “neutral” rating to an “underperform” rating in a report on Friday, June 5th. Berenberg Bank reissued a “buy” rating on shares of Smith & Nephew in a report on Friday, July 10th. Finally, Bank of America raised shares of Smith & Nephew from a “neutral” rating to a “buy” rating in a research note on Wednesday. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $48.00.
About Smith & Nephew
Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.
Recommended Story: What defines an oversold asset?
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.